Hansa Biopharma — Oktober 2025
-
Analyst Consensus på Hansa Biopharma's egen hjemmeside:
Analysts and consensus | Hansa Biopharma
We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.
(www.hansabiopharma.com)
Price target (medianen): SEK 97 og med hele 6 købsanbefalinger (uden Redeye) ..
-
Hansa Biopharma: Jefferies inleder bevakning på Hansa Biopharma med köp och riktkurs 100 kronor.https://www.nordnet.dk/markedet/nyheder/fac00fdf-3379-4320-bb22-17c269e83f93
-
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
• Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
• First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene therapy. -
Hansa Biopharma: ”Pengarna räcker in i 2027”
Hansa Biopharma: ”Pengarna räcker in i 2027”
Hansa Biopharma: ”Pengarna räcker in i 2027”| Håll dig uppdaterad med aktuella ekonominyheter – gratis.
EFN.se (efn.se)
-
I starten af året oplyste Hansa også de havde penge til 2026, det viste sig jo slet ikke at passe. Så man skal nok heller ikke regne med der penge til 2027. Slet ikke når de ikke kan mindske omkostningerne som de også har sagt de ville. Heldigt René fik hævet lidt flere penge ind så hun da er sikkert sin kæmpe løn
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind